Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-720-9 | CAS number: 29598-76-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 April 2017 to 25 April 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- OECD GUIDELINES FOR TESTING OF CHEMICALS (No.: 402, 24th Feb. 1987)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- Commission Regulation (EC) No 440/2008, B.3 (L 142, 30 May 2008)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Version / remarks:
- OPPTS 870.1200 (EPA 712-C-98-192, August 1998)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- 2,2-bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate]
- EC Number:
- 249-720-9
- EC Name:
- 2,2-bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate]
- Cas Number:
- 29598-76-3
- Molecular formula:
- C65H124O8S4
- IUPAC Name:
- 2,2-bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate]
- Test material form:
- solid
- Details on test material:
- Name: 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate]
CAS number: 29598-76-3
Batch/Lot Number: 1005151109
Description: White to off-white pellet
Manufacture date: 13 November 2015
Expiry date: 12 November 2019
Purity*: Considered as 100%
Storage condition: Controlled room temperature (15-25 ºC, below 70 RH%)
Safety precautions: Routine safety precautions (lab coat, gloves, safety glasses, face mask) for unknown materials were applied to assure personnel health and safety.
*No correction for purity of the test item was applied.
Constituent 1
- Specific details on test material used for the study:
- No further details specified.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl:WI Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level at arrival: SPF
Hygienic level during the study: Standard housing conditions
Justification of strain: The Wistar rat is one of the standard rodent species used in acute toxicity studies.
Number of animals: 5 animals/sex
Sex: Male and female, female rats were nulliparous and non-pregnant.
Age of animals at dosing: Young adult rats
Body weight range at dosing: Between 218 g and 254 g
Acclimation time: 5 days
Husbandry
Animal health: Only healthy animals were used for the study.
The staff Veterinarian certified the health status.
Room-Box: 242/7
Housing: Individual caging
Cage type: Type II. polypropylene/polycarbonate
Bedding: Lignocel 3/4-S Hygienic Animal Bedding was available to animals during the study. Copy of the Certificate of Analysis is retained in the archive at CiToxLAB Hungary Ltd.
Nesting: Nest building material Arbocel Crinklets natural was available to animals during the study. Copy of the Certificate of Analysis is retained in the archive at CiToxLAB Hungary Ltd.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.4–24.7°C
Relative humidity: 30–58%
Ventilation: 15-20 air exchanges/hour
Enrichment: Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities.
Temperature and relative humidity were recorded twice daily during the study.
Food and Water Supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance", ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study and the water was considered fit for human consumption.
The batch of feed employed in the study was as follow:
• 285 17890, expiry date: 31 August 2017
The supplier provided an analytical certificate for the batch used. A copy of the certificate will be archived with the raw data.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service. The quality control results are retained in the archives at CiToxLAB Hungary Ltd.
Animal Identification
Animals were individually identified using numbers written on the tail with an indelible pen. The numbers were given on the basis of CiToxLAB Hungary Ltd.'s Master File for each animal allocated to the treatment groups. The cages were identified by cards containing information about study code, sex, dose group, cage number and individual animal number.
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- Formulation
The test item was powdered and administered as a single dose. Sufficient water was used to dampen the test material to ensure good contact with the skin.
Procedure
The back of each animal was shaved (approximately 10% area of the total body surface) approximately 24 hours prior to treatment. The test item was applied to the shaved skin as a single dose and remained in contact with the skin for the 24-hour exposure period. Sterile gauze pads were placed on the skin of rats to cover the test item. These gauze pads were kept in contact with the skin using a patch with adhesive hypoallergenic plaster. The entire trunk of the animal was then wrapped with semi occlusive plastic wrap for 24 hours.
At the end of the exposure period, the treated area of skin with the test item was washed with water at body temperature. - Duration of exposure:
- A single dermal application was made.
- Doses:
- The test item was not expected to be lethal at 2000 mg/kg bw. A limit test was therefore performed.
- No. of animals per sex per dose:
- 10 (5 males/5 females)
- Control animals:
- not required
- Details on study design:
- OBSERVATIONS
Clinical Observations
Clinical observations were performed on the day of treatment at 1 and 5 hours after application of the test item and once each day for 14 days thereafter.
Observations included the skin and fur, eyes and mucous membranes, the respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Skin Irritation
Adverse skin reactions at the site of application were recorded daily following the removal of the dressing.
Measurement of Body Weight
The body weights were recorded on Day 0 (before test item administration) and on Days 7 and 14 just before necropsy.
NECROPSY
Macroscopic examination was performed on all animals. All animals were anaesthetised with pentobarbital sodium and exsanguinated.
Following confirmation of death, after examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed. All macroscopic changes were recorded. - Statistics:
- The method used was not intended to allow the calculation of a precise LD50 value.
Body weight and body weight gain are summarised in tabular form. Clinical signs and necropsy findings are described and summarised in tabular form.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test item did not cause mortality at the dose level of 2000 mg/kg bw.
- Clinical signs:
- There were no systemic clinical signs noted in any animal throughout the study.
- Body weight:
- There were no treatment related effects on body weight or body weight gain during the observation period.
- Gross pathology:
- There was no evidence of any gross observations at a dose level of 2000 mg/kg bw.
- Other findings:
- Local Dermal Signs
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
Any other information on results incl. tables
Clinical Observations
DOSE LEVEL: 2000 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Observations |
Observations days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
1 |
7960 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
2 |
7961 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
3 |
7962 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
4 |
7963 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
5 |
7964 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
DOSE LEVEL: 2000 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Observations |
Observations days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
6 |
7975 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
7 |
7976 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
8 |
7977 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
9 |
7978 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
10 |
7979 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
Remarks: + = present
h = hour Treatment day = Day 0
Frequency of observation = number of occurrence of observation / total number of observations
Body Weight Data
DOSE LEVEL: 200 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
1 |
7960 |
220 |
252 |
290 |
32 |
38 |
70 |
2 |
7961 |
244 |
300 |
353 |
56 |
53 |
109 |
3 |
7962 |
251 |
300 |
350 |
49 |
50 |
99 |
4 |
7963 |
230 |
279 |
325 |
49 |
46 |
95 |
5 |
7964 |
224 |
263 |
296 |
39 |
33 |
72 |
Mean: |
233.8 |
278.8 |
322.8 |
45.0 |
44.0 |
89.0 |
|
Standard deviation: |
13.2 |
21.6 |
29.4 |
9.5 |
8.3 |
17.2 |
DOSE LEVEL: 200 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
6 |
7975 |
233 |
235 |
247 |
2 |
12 |
14 |
7 |
7976 |
222 |
227 |
234 |
5 |
7 |
12 |
8 |
7977 |
218 |
235 |
252 |
17 |
17 |
34 |
9 |
7978 |
232 |
233 |
239 |
1 |
6 |
7 |
10 |
7979 |
254 |
259 |
302 |
5 |
43 |
48 |
Mean: |
231.8 |
237.8 |
254.8 |
6.0 |
17.0 |
23.0 |
|
Standard deviation: |
14.0 |
12.3 |
27.3 |
6.4 |
15.2 |
17.3 |
Macroscopic Findings
DOSE LEVEL: 2000 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ / Tissue |
1 |
7960 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
2 |
7961 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
3 |
7962 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
4 |
7963 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
5 |
7964 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
DOSE LEVEL: 2000 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ / Tissue |
6 |
7975 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
7 |
7976 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
8 |
7977 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
9 |
7978 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
10 |
7979 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats.
- Executive summary:
An acute dermal toxicity study was performed with the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Crl:WI Wistar rats, in compliance with OECDGuideline No.: 402.
A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex). The test item was powdered and applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 1 and 5 hours after dosing and daily for 14 days thereafter. Body weight was measured prior to dosing on Day 0 and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at the end of the 2-week observation period (Day 14).
The results of the study were summarised as follows:
Mortality
Test item did not cause mortality at the dose level of 2000 mg/kg bw.
Systemic clinical signs
There were no systemic clinical signs noted in any animal throughout the study.
Local dermal signs
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
Body weight and body weight gain
There were no treatment related effects on body weight or body weight gain during the observation period.
Necropsy
There was no evidence of any gross observations at a dose level of 2000 mg/kg bw.
Conclusions
The acute dermal median lethal dose (LD50) of the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats.
According to the GHS criteria, 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] can be ranked as "Category 5" or "Unclassified" for acute dermal exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
